• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New FDA guidance issued for compounding certain animal drugs from bulk drug substances

November 19, 2019
Jill Murphy, Assistant Editor

FDA draft guidance allows for an animal drug to be compounded from bulk drug substances in limited circumstances for which there is no FDA-approved treatment.

The FDA today issued a draft guidance that addresses instances in which the agency does not intend to take action for violations by pharmacists and veterinarians compounding or overseeing the compounding of animal drugs from bulk drug substances. Under the Federal Food, Drug and Cosmetic Act (FD&C Act), compounding an animal drug from bulk drug substances results in a new medication that must comply with the FD&C Act's approval. In addition, all animal drugs are required to be made in accordance with current good manufacturing practice (cGMP) requirements and have adequate directions for use, according to the FDA.

The new guideline is intended to provide additional information and clarity for veterinarians and pharmacists regarding the FDA's current enforcement actions that address animal drug compounding from bulk drug substances. If passed, the policies in the proposed guidance would define situations in which veterinarians are acting within a valid veterinarian-client-patient relationship (VCPR) and for which there is no medically appropriate drug that is FDA-approved to treat the animal.

This policy would also address the FDA's concerns with compounding animal drugs from bulk drug substances, including significant concerns with these medications when they present particular human or animal safety concerns; are intended for use in food-producing animals; are copies of marketed FDA-approved, conditionally approved, or indexed drugs; or are compounded without a patient-specific prescription.

In order to be legally marketed currently, animal drugs, with few exceptions, must be approved by the FDA under section 512 of the FD&C Act, conditionally approved by the FDA under section 571 of the FD&C Act, or indexed under section 572 of the FD&C Act. The FDA-approved animal drugs are subject to requirements once they are on the market, in addition to a pre-market review. Reports of adverse events and manufacturing quality throughout the lifetime of the product allow the FDA to continue to monitor the safety and efficacy of the drug after approval.

The guidance provisions will require the FDA to review the data regarding the safety and efficacy of a product before it qualifies for a conditional approval or indexing process.

Advertisement

For more information on the guidance, click here.

Reference

1.Compounding animal drugs from bulk drug substances-guidance for industry. FDA website. https://www.fda.gov/media/132567/download. Published November 2019. Accessed November 19, 2019.

Related Content:

Breaking News
The new Shreiber School of Veterinary Medicine breaks ground
The new Shreiber School of Veterinary Medicine breaks ground
Fentanyl combined with xylazine designated an emerging threat to the United States
Fentanyl combined with xylazine designated an emerging threat to the United States
Veterinarian kills 2 police officers in Mississippi
Veterinarian kills 2 police officers in Mississippi

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement